<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02479217</url>
  </required_header>
  <id_info>
    <org_study_id>ML20367</org_study_id>
    <nct_id>NCT02479217</nct_id>
  </id_info>
  <brief_title>Safety of Xeloda in Solid Tumours</brief_title>
  <official_title>Safety of Xeloda in Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to observe safety and tolerability of Xeloda as used
      in medical practice, alone and in combination with docetaxel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>within 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>within 18 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1268</enrollment>
  <condition>Metastatic Breast Cancer, Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant therapy</arm_group_label>
    <description>Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <description>Patients prescribed Xeloda with docetaxel for metastatic breast cancer after failure to anthacyclines were observed until disease progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <description>Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xeloda</intervention_name>
    <arm_group_label>Adjuvant therapy</arm_group_label>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with early or metastatic colon cancer, and patients with metastatic breast cancer,
        no age limit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Metastatic Breast Cancer:

          -  women &gt;=18 years of age

          -  Patients with locally advanced or metastatic breast cancer after failure of cytotoxic
             chemotherapy.

          -  Previous therapy should have included an anthracycline.

          -  Patients with locally advanced or metastatic breast cancer after failure of taxanes
             and an anthracycline-containing chemotherapy regimen or for whom further anthracycline
             therapy is not indicated.

          -  Female patients with histopathologically proven metastatic breast cancer

          -  Adequate bone marrow, liver, renal and cardiac functions

        Colon Cancer:

          -  Patients &gt;18 years of age

          -  Patients with histologicaly confirmed colon cancer

          -  Patients with potential curative tumor resection within 8 weeks before enrolment in
             the study

          -  Patients previously not treated with chemiotherapy

        Exclusion Criteria:

        Metastatic Breast Cancer:

          -  Patients previously treated with docetaxel (Taxotere) or capecitabine (Xeloda)

          -  Patients with contraindications for any of study drugs as listed in approved SmPC

        Colon Cancer:

          -  Patients previously treated with chemiotherapy

          -  Patients with contraindications for study drug as listed in approved SmPC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2015</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

